Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.

[1]  Jacob S. Young,et al.  A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors , 2015, Scientific Reports.

[2]  S. Gool.  Brain Tumor Immunotherapy: What have We Learned so Far? , 2015, Front. Oncol..

[3]  S. V. Van Gool.  Brain Tumor Immunotherapy: What have We Learned so Far? , 2015, Frontiers in oncology.

[4]  I. Balyasnikova,et al.  IL13 Receptor α2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis. , 2015, Cancer research.

[5]  J. Bading,et al.  Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma , 2015, Clinical Cancer Research.

[6]  S. Riddell,et al.  Designing chimeric antigen receptors to effectively and safely target tumors. , 2015, Current opinion in immunology.

[7]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[8]  J. Sampson,et al.  Immunotherapy for malignant glioma , 2015, Surgical neurology international.

[9]  K. Kelly-Spratt,et al.  Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD , 2015, Cancer Immunology Research.

[10]  P. Wen,et al.  Immunotherapy advances for glioblastoma. , 2014, Neuro-oncology.

[11]  S. Gottschalk,et al.  T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1. , 2014, Cytotherapy.

[12]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[13]  Katherine K. Matthews,et al.  Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. , 2014, Cancer research.

[14]  Pradip Bajgain,et al.  Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  S. Gottschalk,et al.  Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.

[16]  S. Rosenberg,et al.  EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss , 2013, Clinical Cancer Research.

[17]  Xutao Deng,et al.  Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis , 2013, PloS one.

[18]  S. Rosenberg,et al.  Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy , 2013, Clinical Cancer Research.

[19]  C. Lau,et al.  Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. , 2013, Neuro-oncology.

[20]  Y. Kew,et al.  Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Matthew L Baker,et al.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.

[22]  S. Riddell,et al.  Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells , 2013, Clinical Cancer Research.

[23]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[24]  R. Grossman,et al.  T cells redirected to EphA2 for the immunotherapy of glioblastoma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  I. Pastan,et al.  Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. , 2013, Blood.

[26]  Jinyuan Zhou,et al.  Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells , 2012, Clinical Cancer Research.

[27]  Gina Lee,et al.  Characterization and Immunotherapeutic Implications for a Novel Antibody Targeting Interleukin (IL)-13 Receptor α2* , 2012, The Journal of Biological Chemistry.

[28]  J. Casal,et al.  High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. , 2012, Cancer research.

[29]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[30]  S. Forman,et al.  Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells , 2012, Clinical Cancer Research.

[31]  M. Vogelbaum,et al.  Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling , 2011, Molecular Cancer Therapeutics.

[32]  S. Gottschalk,et al.  Cellular immunotherapy for high-grade glioma. , 2011, Immunotherapy.

[33]  R. Puri,et al.  Targeting IL‐13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL‐13‐PE and gemcitabine , 2011, International journal of cancer.

[34]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Rosenberg,et al.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.

[36]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Mosser,et al.  Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions , 2010, Journal of Neuroimmunology.

[38]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[39]  R. Grossman,et al.  HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors , 2010, Clinical Cancer Research.

[40]  R. Puri,et al.  Targeting IL-13Rα2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin , 2008, Molecular Cancer Therapeutics.

[41]  R. Puri,et al.  Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. , 2008, Neuro-oncology.

[42]  I. Pollack,et al.  Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas , 2008, Journal of Neuro-Oncology.

[43]  Mitchel S Berger,et al.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. James,et al.  Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.

[45]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[46]  H. Heslop,et al.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  S. Forman,et al.  Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.

[48]  R. Puri,et al.  Analysis of interleukin‐13 receptor α2 expression in human pediatric brain tumors , 2004, Cancer.

[49]  C. Sample,et al.  An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. , 2001, Blood.

[50]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[51]  R. Puri,et al.  IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. , 2006, Nature medicine.